Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule product candidates primarily to treat cancer. Co. has three clinical-stage product candidates and preclinical programs. Substantially all of Co.'s effort is focused on its primary product candidate, rigosertib, which has been tested in an intravenous formulation as a single agent for patients with higher-risk myelodysplastic syndromes (MDS), and an oral formulation as a single agent in lower risk MDS or in combination with azacitidine for patients with higher-risk MDS. Co.'s other product candidate, Briciclib, is a small molecule targeting an intracellular regulatory protein, Cyclin D1. The ONTX stock yearly return is shown above.
The yearly return on the ONTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ONTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|